实时三平面定量组织速度成像及实时三平面应变率成像技术评价尿毒症患者左室舒张功能  

Real-time three-plane quantitative tissue velocity imaging and real-time three-plane strain rate imaging in assessing left ventricular diastolic function in patients with uremia

作　　者：姚文[1] 郑慧[1] 帅秀芳[1] 靳松[1] 姚翀[1] 王迪[1] 李晓金[1] 

机构地区：[1]安徽医科大学第一附属医院超声科,合肥230022

出　　处：《安徽医科大学学报》2014年第1期92-96,共5页Acta Universitatis Medicinalis Anhui

基　　金：安徽省高校自然科学基金重点项目(编号:KJ2010A175)

摘　　要：目的应用实时三平面(RT-3PE)定量组织速度成像(QTVI)及实时三平面应变率(SRI)成像技术定量分析尿毒症患者左室舒张功能。方法收集30例尿毒症患者和33例健康志愿者的心尖四腔观RT-3PE图像。应用RT-3PE QTVI和RT-3PE SRI技术分别测量左心室各室壁基底段和中间段心肌舒张早期和舒张晚期峰值速度(Ve、Va)及峰值应变率(SRe、SRa),计算Ve/Va和SRe/SRa,然后进行比较分析。结果与正常对照组相比,尿毒症组的Ve、SRe明显降低(P<0.05),Ve/Va、SRe/SRa显著降低(P<0.05),Va升高(P<0.05),而SRa变化差异无显著性。结论 RT-3PE QTVI技术和RT-3PE SRI技术通过舒张期峰值速度、峰值应变率等指标能更加准确地评价尿毒症患者左室舒张功能。Objective To analyze left ventricular diastolic function in patients with uremia by real-time quantitative tissue velocity imaging and real-time three-plane strain rate imaging. Methods Real-time three-plane three -plane apical 4-chamber views of 30 uremia patients and 33 healthy volunteers were obtained. Early diastolic peak velocity （Ve） ,late diastolic peak velocity （Va） and early diastolic peak strain rate （SRe）, late diastolic peak strain rate （SRa） at basal and middle segments of different left ventricular walls were measured using real-time three-plane quantitative tissue velocity imaging and real-time three-plane strain rate imaging,and Ve/Va, SRe/SRa were calculated. Then all the data were compared and analyzed. Results Compared with control group, Ve and SRe in uremia group were significantly lower（P 〈0. 05 ）, Ve/Va and SRe/SRa were significantly lower（ P 〈0. 05 ）, Va were higher（P 〈 0. 05 ） ,but SRa were no significant change. Conclusion Real-time three-plane quantitative tissue velocity imaging and real-time three-plane strain rate imaging can assess left ventricular diastolic function of uremia patients more accurately through indicators such as diastolic peak velocity, diastolic peak strain rate.

关 键 词：定量组织速度成像 应变率成像 左室舒张功能 尿毒症 

分 类 号：R540.45[医药卫生—心血管疾病] R692.5[医药卫生—内科学]